In lung cancer, a rapid decrease in the serum concentration of mutated EGFR-DNA 14 days after initiating treatment with erlotinib (a tyrosine kinase inhibitor) was associated with tumour shrinkage 2 months later [36]. Here, EGFR is linked to lung cancer.